Literature DB >> 27241106

Gynecologic Manifestations of the DICER1 Syndrome.

Colin J R Stewart1, Adrian Charles2, William D Foulkes3.   

Abstract

Patients with germline DICER1 mutations are at increased risk of developing a wide range of tumors, most of which are relatively rare in the general population. In the gynecologic tract, these include ovarian sex cord-stromal tumors, particularly Sertoli-Leydig cell tumor, and embryonal rhabdomyosarcoma of the cervix. In some cases, these are the sentinel neoplasms. DICER1-associated tumors may have distinctive morphologic appearances that may prompt the pathologist to consider an underlying tumor predisposition syndrome and therefore consideration of genetic evaluation in the patient and her family.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervix; DICER1; Mutation; Ovary; Rhabdomyosarcoma; Sertoli-Leydig cell tumor; Syndrome

Mesh:

Substances:

Year:  2016        PMID: 27241106     DOI: 10.1016/j.path.2016.01.002

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  12 in total

1.  DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.

Authors:  Kris Ann P Schultz; Anne K Harris; Michael Finch; Louis P Dehner; Jubilee B Brown; David M Gershenson; Robert H Young; Amanda Field; Weiying Yu; Joyce Turner; Nicholas G Cost; Dominik T Schneider; Douglas R Stewart; A Lindsay Frazier; Yoav Messinger; D Ashley Hill
Journal:  Gynecol Oncol       Date:  2017-10-14       Impact factor: 5.482

Review 2.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

3.  MicroRNAs in Genetic Etiology of Human Diseases.

Authors:  Melis Olcum; Kemal Ugur Tufekci; Sermin Genc
Journal:  Methods Mol Biol       Date:  2022

4.  Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.

Authors:  Melissa A Merideth; Laura A Harney; Nina Vyas; Averyl Bachi; Ann Garrity Carr; D Ashley Hill; Louis P Dehner; Kris Ann P Schultz; Douglas R Stewart; Pamela Stratton
Journal:  Gynecol Oncol       Date:  2020-01-15       Impact factor: 5.482

5.  Significantly greater prevalence of DICER1 alterations in uterine embryonal rhabdomyosarcoma compared to adenosarcoma.

Authors:  Leanne de Kock; Ju-Yoon Yoon; Blaise A Clarke; William D Foulkes; Maria Apellaniz-Ruiz; Dylan Pelletier; W Glenn McCluggage; Colin J R Stewart; Brendan C Dickson; Marjan Rouzbahman
Journal:  Mod Pathol       Date:  2020-01-03       Impact factor: 7.842

Review 6.  Imaging of DICER1 syndrome.

Authors:  R Paul Guillerman; William D Foulkes; John R Priest
Journal:  Pediatr Radiol       Date:  2019-10-16

7.  Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly via Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling.

Authors:  Steven D Klein; Julian A Martinez-Agosto
Journal:  Microrna       Date:  2020

Review 8.  Regulatory Mechanism of MicroRNA Expression in Cancer.

Authors:  Zainab Ali Syeda; Siu Semar Saratu' Langden; Choijamts Munkhzul; Mihye Lee; Su Jung Song
Journal:  Int J Mol Sci       Date:  2020-03-03       Impact factor: 5.923

9.  Genomics of a pediatric ovarian fibrosarcoma. Association with the DICER1 syndrome.

Authors:  Jorge Melendez-Zajgla; Gabriela E Mercado-Celis; Javier Gaytan-Cervantes; Amada Torres; Nayeli Belem Gabiño; Martha Zapata-Tarres; Luis Enrique Juarez-Villegas; Pablo Lezama; Vilma Maldonado; Karen Ruiz-Monroy; Elvia Mendoza-Caamal
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

Review 10.  Dicing the Disease with Dicer: The Implications of Dicer Ribonuclease in Human Pathologies.

Authors:  Eleni I Theotoki; Vasiliki I Pantazopoulou; Stella Georgiou; Panos Kakoulidis; Vicky Filippa; Dimitrios J Stravopodis; Ema Anastasiadou
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.